In its 1Q18 earnings, Shire plc (LSE:SHP; NASDAQ:SHPG) released its first figures since splitting its neuroscience and rare disease businesses into two divisions (see BioCentury Extra, Jan. 9) . For the quarter, Shire's rare disease division...

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global...

Allergan plc (NYSE:AGN) announced details Thursday of a plan to reduce costs as it braces for potential generic competition to its blockbuster dry eye drug Restasis cyclosporine this year. The company will cut over 1,000...

Allergan plc (NYSE:AGN) announced details Thursday of a plan to reduce costs as it braces for potential generic competition to its blockbuster dry eye drug Restasis cyclosporine this year. The company will cut over 1,000...

In a May inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board (PTAB) invalidated all claims in U.S. Patent 8,865,688 covering ulcerative colitis (UC) drug Apriso granulated mesalamine from Valeant Pharmaceuticals International...

The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO) upheld the validity of the only Orange Book-listed patent for ulcerative colitis drug Lialda mesalamine from Shire. PTAB evaluated an inter...

The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office upheld the validity of the only Orange Book-listed patent for ulcerative colitis drug Lialda mesalamine from Shire plc (LSE:SHP; NASDAQ:SHPG). PTAB evaluated...

The U.S. Supreme Court will hear arguments on Monday in a case that could either overturn or reinforce policies that unfairly tilt the inter partes review system against patent holders, according to life sciences companies....

The U.S. District Court for the District of Southern Florida upheld a patent protecting Shire’s ulcerative colitis drug Lialda mesalamine and granted an injunction blocking approval and sale of a generic form of the drug...

The U.S. District Court of Southern Florida upheld a patent protecting ulcerative colitis drug Lialda mesalamine from Shire plc (LSE:SHP; NASDAQ:SHPG) and granted an injunction blocking approval and sale of a generic form of the...